If FCR will be the cure of selection, warning has to be taken in people with NOTCH1 mutations, in whom rituximab appears to acquire small extra benefit.59 Other genomic subgroups, for example patients with BIRC3 mutations look to derive little gain from CIT,111,112 but these final results need to be